GlassScriptPhysician profile
Carmine Gianatiempo
NPI 1558310748
$6,621.38
in general payments reported to CMS, 2019-2025
22 companies · $905 in 2025
The $905 reported for 2025 was more than what 76% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,211 · 2020: $204 · 2021: $26.75 · 2022: $2,091 · 2023: $82.78 · 2024: $102 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800 · Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
| Food and Beverage | $288.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $2,783.16 | 2019 | |
| La Jolla Pharmaceutical Company | $1,826.46 | 2022-2024 | Giapreza |
| Becton, Dickinson and Company | $800.00 | 2025 | |
| Zoll Medical Corporation | $245.00 | 2019 | |
| Abiomed | $185.75 | 2019-2025 | |
| Cumberland Pharmaceuticals, INC. | $151.83 | 2019-2025 | Caldolor |
| Abbvie INC. | $120.01 | 2022 | |
| Chiesi USA, INC. | $113.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $89.23 | 2019-2025 | Bridion, Zerbaxa |
| Nuwellis, INC. | $71.77 | 2020 | |
| Csl Behring | $45.58 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $32.82 | 2023-2025 | Exparel, Zilretta, Iovera |
| Edwards Lifesciences Corporation | $32.33 | 2020 | |
| Portola Pharmaceuticals, LLC | $15.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $14.62 | 2020 | |
| Amgen INC. | $13.89 | 2019 | |
| Heron Therapeutics, INC. | $13.78 | 2022 | |
| Baudax Bio INC. | $13.63 | 2020 | |
| Allergan, INC. | $13.41 | 2019 | |
| Amarin Pharma, INC. | $12.90 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmine Gianatiempo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.